Revenue by quarter
US$ · last 8Hover a column for its exact figure
$0$500M$1B$1.5B
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $360.5M | $83.5M | 0.92 |
| Q1 FY2026 | $272.6M | -$2.8M | -0.03 |
| Q4 FY2025 | $164.7M | -$135.0M | -1.67 |
| Q3 FY2025 | $211.0M | $15.9M | 0.20 |
Newest filings
All 358| Form | Filed | |
|---|---|---|
| 8-K | 21 Sep 2026 | |
| 8-K | 28 Aug 2026 | |
| 8-K | 13 Aug 2026 | |
| 10-Q | 30 Jul 2026 | |
| 8-K | 30 Jul 2026 | |
| 8-K | 18 Jun 2026 | |
| 8-K | 16 Jun 2026 | |
| 8-K | 9 Jun 2026 |
Description
- Ticker
- PTCT-US
- Exchange
- Nasdaq
- Index
- S&P SmallCap 600
- Industry
- Pharmaceutical Preparations
- SIC division
- Manufacturing
- CIK
- 0001070081
- LEI
- 549300UJLWOIWFDGB318
- FIGI
- BBG000QT15P7
- Share class FIGI
- BBG001SNNC86
- Fiscal year ends
- Dec
- Filings held
- 358 since 2004
- 8-K events
- 170
- Shares short
- 9.2M, 30 Sep 2026
Financial statements
The income statement, balance sheet and cash flow by year and by quarter, line by line as the company reports them. Each column names the filing it comes from.
34 lines · 15 years · US$ millionsJSON
| Fiscal period | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Filed | 6 Mar 2014 | 2 Mar 2015 | 29 Feb 2016 | 16 Mar 2017 | 6 Mar 2018 | 1 Mar 2019 | 2 Mar 2020 | 25 Feb 2021 | 22 Feb 2022 | 21 Feb 2023 | 29 Feb 2024 | 27 Feb 2025 | 19 Feb 2026 | 19 Feb 2026 | 19 Feb 2026 |
| +Total revenues | 105M | 34Mr | 35Mr | 25M | 37M | 83M | 194M | 265M | 307M | 381M | 539M | 699M | 938M | 807M | 1,731M |
| +Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | – | – | – | – | – | – | – | 13M | 12M | 19M | 32M | 45M | 66M | 57M | 47M |
| +Amortization of acquired intangible assets | – | – | – | – | 0M | 0M | 15M | 23M | 28M | 37M | 55M | 117M | 223M | 61M | 25M |
| +Research and development | 59M | 46Mr | 55Mr | 80M | 122M | 118M | 118M | 172M | 258M | 478M | 541M | 652M | 667M | 535M | 455M |
| +Selling, general and administrative | 16M | 15Mr | 25Mr | 45M | 82M | 97M | 121M | 154M | 203M | 245M | 286M | 326M | 333M | 301M | 347M |
| −Change in the fair value of contingent consideration | – | – | – | – | – | 0M | 0M | -19M | -48M | -23M | 0.5M | 26M | 128M | 4.5M | 0.8M |
| +Intangible asset impairment | – | – | – | – | – | – | – | – | – | – | – | 33M | 218M | 160M | – |
| −Tangible asset impairment and losses on transactions, net | – | – | – | – | – | – | – | – | – | 11M | – | – | – | -0.7M | 9.6M |
| −Total operating expenses | 75M | 61Mr | 80Mr | 125M | 204M | 215M | 259M | 380M | 548M | 813M | 913M | 1,146M | 1,377M | 1,109M | 864M |
| Income from operations | 31M | -27Mr | -45Mr | -99M | -167M | -132M | -64M | -116M | -241M | -432M | -374M | -447M | -440M | -303M | 867M |
| % of total revenues | 29.0% | -79.0% | -130.8% | -393.8% | -454.6% | -159.7% | -33.1% | -43.7% | -78.6% | -113.4% | -69.5% | -64.0% | -46.9% | -37.5% | 50.1% |
| +Interest expense, net | -2.4M | -1.2Mr | -6.1Mr | 1.2M | -2.4M | -8.3M | -12M | -13M | -13M | -56M | -86M | -91M | -129M | -167M | -152M |
| +Other income, net | 0.5M | 1.8Mr | 0Mr | -0.2M | -0.5M | -1.2M | -1.3M | 0.1M | 14M | 85M | -58M | -49M | 10M | 6.5M | -18M |
| +Gain on sale of priority review voucher | – | – | – | – | – | – | – | – | – | – | – | – | – | 100M | – |
| +Loss on extinguishment of debt | – | – | -0.1Mr | – | – | – | – | – | – | – | – | – | -138M | – | – |
| Income before income tax benefit | 29M | -26Mr | -52Mr | -98M | -170M | -142M | -78M | -128M | -240M | -403M | -518M | -588M | -696M | -363M | 697M |
| % of total revenues | 27.1% | -77.3% | -148.6% | -390.0% | -462.3% | -171.1% | -40.0% | -48.4% | -78.2% | -105.8% | -96.2% | -84.1% | -74.2% | -45.0% | 40.3% |
| −Income tax benefit | -2.3M | – | – | -4.7M | 0.5M | 0.6M | 1.3M | -0M | 12M | 35M | 5.6M | -29M | -70M | 0.2M | 14M |
| Net income attributable to common stockholders | 31M | -26Mr | -52Mr | -94M | -170M | -142M | -79M | -128M | -252M | -438M | -524M | -559M | -627M | -363M | 683M |
| % of total revenues | 29.3% | -77.3% | -148.6% | -371.4% | -463.6% | -171.8% | -40.6% | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| Basic and diluted | – | – | 13M | 32M | 34M | 34M | 39M | 47M | 59M | 66M | – | – | – | – | – |
| Net loss per share-basic and diluted | – | – | -5.18 | -2.97 | -5.07 | -4.17 | -2.02 | -2.75 | -4.27 | -6.64 | – | – | – | – | – |
| Basic | 0M | 0M | 13M | 32M | – | – | – | – | 59M | 66M | 71M | 72M | 75Mr | 77M | 80M |
| Diluted | 0M | 0M | 13M | 32M | – | – | – | – | 59M | 66M | 71M | 72M | 75Mr | 77M | 88M |
| Basic | 23.95 | 219.76 | -5.18 | -2.97 | – | – | – | – | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 8.58 |
| Diluted | 4.55 | 42.50 | -5.18 | -2.97 | – | – | – | – | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 |
| Revenue | – | – | – | – | – | 83M | 194M | 265M | 307M | – | – | – | – | – | – |
| Cost of Goods and Services Sold | – | – | – | – | – | – | 4.6M | 13M | 12M | – | – | – | – | – | – |
Hover a figure for its source.r restated in a later filing– not reported in that period
Lines in the order and wording of the 10-K filed 19 Feb 2026. 233 of 233 subtotals add up to the company's own totals, and the balance sheet balances in 67 of 67 periods. Newest filing read: 30 Jul 2026.
Free for personal research, with credit (Data by Shikshan Nivesh) and a link. API access, bulk files and commercial use need a licence: the data licence.
Charts
Any figure or ratio in the record, by year, by quarter or on a trailing twelve months, as a value or as growth, against a peer if you like. Hover for the figures.
Revenue · quarterly · US$
Latest Jun 2026: $360.52M
PTCT · PTC Therapeutics, Inc.20132026
Revenue = rev
$360.5M · Jun 2026
101.5% · Jun 2026
32.3% · Jun 2026
96.0% · Dec 2019
GrossOperatingNet
$83.5M · Jun 2026
−$39.7M · Jun 2026
$0.92 · Jun 2026
88.3M · Dec 2025
$2.2B · Jun 2026
CashDebt
−44.5% · Dec 2025
$711.2M · Dec 2025
Operating cash flowCapital spending
Revenue by segment
Net product revenueRoyalty revenueTranslarnaManufacturing revenueCollaboration revenueEach fiscal year as its annual report gives it.
Ratios
Every ratio, worked out the same way for every company, by year or on a trailing twelve months. Hover a ratio for its formula.
145 ratios · 12 in profitabilityJSON
| Fiscal year ending | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on common equity | – | – | −279.5% | −43.1% | −65.0% | −82.2% | −57.2% | −50.5% | −53.2% | −81.4% | −216.7% | 323.5% | 107.5% | 37.9% | −104.7% |
| Return on assets | – | – | −62.5% | −38.7% | −48.8% | −44.8% | −23.9% | −17.0% | −18.3% | −22.9% | −25.3% | −30.7% | −34.8% | −20.2% | 29.7% |
| Return on capital | – | – | −171.5% | −43.5% | −42.8% | −39.0% | −19.6% | −28.7% | −27.0% | −40.1% | −48.3% | −129.5% | 255.5% | 35.5% | −232.3% |
| Return on invested capital | – | – | 69.4% | 836.0% | 697.7% | 597.1% | −105.5% | −59.9% | −76.5% | 750.5% | 90.6% | 161.7% | 49.5% | 14.2% | −44.5% |
| Gross margin | – | – | – | – | 100.0% | 100.0% | 97.6% | 95.2% | 96.0% | – | – | – | – | – | – |
| EBITDA margin | 31.7% | −71.0% | −123.9% | −384.9% | −446.8% | −155.7% | −24.0% | −33.8% | −68.1% | −102.0% | −57.6% | −45.6% | −21.6% | −28.1% | 52.3% |
| Operating margin | 29.0% | −79.0% | −130.8% | −393.8% | −454.6% | −159.7% | −33.1% | −43.7% | −78.6% | −113.4% | −69.5% | −64.0% | −46.9% | −37.5% | 50.1% |
| Incremental operating margin | – | 80.3% | −2477.7% | 571.5% | −587.8% | 76.3% | 60.7% | −73.1% | −297.0% | −258.3% | 36.3% | −45.5% | 3.3% | −104.5% | 126.6% |
| Pretax margin | 27.1% | −77.3% | −148.6% | −390.0% | −462.3% | −171.1% | −40.0% | −48.4% | −78.2% | −105.8% | −96.2% | −84.1% | −74.2% | −45.0% | 40.3% |
| Profit margin | 29.3% | −77.3% | −148.6% | −371.4% | −463.6% | −171.8% | −40.6% | −48.4% | −82.0% | −115.1% | −97.3% | −80.0% | −66.8% | −45.0% | 39.4% |
| Net income to common margin | 29.3% | −77.3% | −148.6% | −371.4% | −463.6% | −171.8% | −40.6% | −48.4% | −82.0% | −115.1% | −97.3% | −80.0% | −66.8% | −45.0% | 39.4% |
| Effective tax rate | −8.1% | – | – | 4.8% | −0.3% | −0.4% | −1.7% | 0.0% | −4.9% | −8.7% | −1.1% | 4.8% | 10.0% | −0.0% | 2.0% |
Hover a ratio for its formula as computed; avg() is the mean of the line now and a year earlier. The bar mark charts it. Worked out the same way for every company, from the standardized statements. Newest filing read: 30 Jul 2026.
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
Key points
Product revenue more than doubled
Total net product revenue across the commercial portfolio was $238.8 million, against $118.3 million a year earlier. Total revenue was $360.5 million, against $178.9 million.
Net income against prior-year loss
Net income was $83.5 million, or $0.92 per diluted share, against a net loss of $64.8 million, or $(0.83) per share, a year earlier.
Full-year revenue guidance raised
Full-year total revenue and product revenue expectations were both raised for 2026. Figures are listed in the guidance section.
Sephience sales rose 21 percent
Sephience net product revenue was $151.3 million, up 21% from the first quarter's $124.6 million. Patients on commercial therapy reached 1,647 at June 30, 2026, against 1,244 at March 31.
Sephience growth shifts beyond the US
Sephience revenue was mostly from the US, with contributions from outside the US increasing. The company said the global launch continues.
Translarna and Emflaza revenue declined
Translarna net product revenue was $42.2 million, against $59.5 million a year earlier. Emflaza was $24.6 million, against $36.4 million, due to continued generic erosion.
Evrysdi royalties grew
Roche reported Evrysdi sales of approximately 968 CHF million year to date. PTC's royalty was $71.1 million for the quarter, against $57.6 million a year earlier.
Non-GAAP R&D expense fell
Non-GAAP R&D expense was $88.6 million, excluding $10.5 million of stock-based compensation, against $104.0 million a year earlier.
GAAP R&D expense declined
GAAP R&D expense was $99.2 million, against $113.0 million in the second quarter of 2025.
SG&A expense lower year over year
GAAP SG&A expense was $80.6 million, against $85.3 million. Non-GAAP SG&A expense was $67.9 million, excluding $12.7 million of stock-based compensation, against $75.7 million.
Votoplam slowed disease at 10 mg
PIVOT-HD 24-month results in Stage 2 participants showed dose-dependent slowing on the cUHDRS scale, reaching 52% at the 10 mg dose level.
Novartis-funded Phase 3 enrolling
Novartis conducts and funds the INVEST-HD Phase 3 study, targeting about 770 people with early symptomatic disease. Its initiation triggered a $50 million milestone payment to PTC in the second quarter.
PTC303 named as development candidate
PTC303 was named as the MSH3 splicing program development candidate, targeting Huntington's disease and myotonic dystrophy.
PTC612 Phase 1 started
The oral NLRP3 inhibitor PTC612 entered a Phase 1 study in the second quarter of 2026.
Guidance
- Total revenue$1.18 to $1.28 billionfull year 2026 · raised from $1.08 to $1.18 billion
- Total net product revenue$850 to $950 millionfull year 2026 · raised from $750 to $850 million
- GAAP R&D and SG&A expense$775 to $815 millionfull year 2026 · kept from $775 to $815 million
- Non-GAAP R&D and SG&A expense$680 to $720 millionfull year 2026 · kept from $680 to $720 million
- Stock-based compensation expense (excluded from non-GAAP expense)$95 millionfull year 2026 · kept from $95 million
In their words
“Our teams delivered another strong quarter enabling us to again raise 2026 product revenue guidance” Matthew B. Klein, M.D., Chief Executive Officer
“We also made a number of advances in our R&D pipeline, including identification of our next small molecule splicing development candidate, PTC303, targeting somatic expansion disorders including Huntington’s disease and myotonic dystrophy.” Matthew B. Klein, M.D., Chief Executive Officer
“In addition, we initiated the Phase 1 study of PTC612, our differentiated NLRP3 small molecule.” Matthew B. Klein, M.D., Chief Executive Officer
Coming up
Vatiquinone study start. The PROVE-FA study is expected to start in Q3 2026.
PTC844 Phase 2a start. The Phase 2a study of PTC844 is expected to start in Q3 2026.
FDA engagement on PIVOT-HD. PTC plans to engage with the FDA in the second half of 2026 on the PIVOT-HD 24-month results, which are being finalized.
PTC303 clinic entry. PTC303 is planned to enter the clinic in 2027.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
By product, FY2024
- Net product revenue$601.0M 74.5%
- Royalty revenue$203.9M 25.3%
- Manufacturing revenue$1.7M 0.2%
- Collaboration revenue$304.0K 0.0%
9 years held, FY2016 to FY2024
By region, FY2024
- United States$413.0M 51.2%
- Non-US$393.7M 48.8%
10 years held, FY2015 to FY2024
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 21 Sep 2026 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | |
| 28 Aug 2026 | 8-K | Material agreement | 1.01 | |
| 13 Aug 2026 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | |
| 30 Jul 2026 | 8-K | ResultsLeadership changeInvestor update | 2.02, 5.02, 7.01, 9.01 | |
| 18 Jun 2026 | 8-K | Material agreementNew debtShare saleOther events | 1.01, 2.03, 3.02, 8.01, 9.01 | |
| 16 Jun 2026 | 8-K | Other events | 8.01, 9.01 | |
| 9 Jun 2026 | 8-K | Leadership change | 5.02, 9.01 | |
| 5 Jun 2026 | 8-K | Shareholder vote | 5.07 | |
| 7 May 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 28 Apr 2026 | 8-K | Investor update | 7.01, 9.01 | |
| 25 Mar 2026 | 8-K | Leadership changeInvestor update | 5.02, 7.01, 9.01 | |
| 19 Feb 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 12 Feb 2026 | 8-K | Investor update | 7.01, 9.01 | |
| 12 Jan 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 29 Dec 2025 | 8-K | Material agreement | 1.01 | |
| 4 Nov 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 19 Aug 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 7 Aug 2025 | 8-K | Material agreement | 1.01 | |
| 7 Aug 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 28 Jul 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 17 Jun 2025 | 8-K | Shareholder vote | 5.07 | |
| 6 May 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 5 May 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 28 Mar 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 27 Feb 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 13 Jan 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 3 Jan 2025 | 8-K | Material agreementNew debt | 1.01, 2.03 | |
| 2 Dec 2024 | 8-K | Material agreementInvestor update | 1.01, 7.01, 9.01 | |
| 27 Nov 2024 | 8-K | Material agreementInvestor update | 1.01, 7.01, 9.01 | |
| 7 Nov 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 18 Oct 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 8 Aug 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 28 Jun 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 20 Jun 2024 | 8-K | Material agreementShareholder voteInvestor update | 1.01, 5.07, 7.01, 9.01 | |
| 20 May 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 25 Apr 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 29 Feb 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 25 Jan 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 8 Jan 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 26 Oct 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 19 Oct 2023 | 8-K | Agreement ended | 1.02, 9.01 | |
| 19 Oct 2023 | 8-K | Material agreementInvestor updateOther events | 1.01, 7.01, 8.01, 9.01 | |
| 28 Sep 2023 | 8-K | RestructuringInvestor update | 2.05, 7.01, 9.01 | |
| 22 Sep 2023 | 8-K | Other events | 8.01, 9.01 | |
| 15 Sep 2023 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | |
| 3 Aug 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 19 Jul 2023 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | |
| 17 Jul 2023 | 8-K | Leadership change | 5.02, 9.01 | |
| 21 Jun 2023 | 8-K | Investor update | 7.01, 9.01 | |
| 6 Jun 2023 | 8-K | Shareholder vote | 5.07, 9.01 |
1–50 of 150
8-K events each year
Hover a column for its exact count
05101520
'13'17'21'25'26
Every filing
The company's filings with the SEC, newest first: 358 held. Insider, fund and large-holder filings have their own tables below.
| 21 Sep 2026 | 8-K | 21 Sep 2026 | |
| 28 Aug 2026 | 8-K | 25 Aug 2026 | |
| 13 Aug 2026 | 8-K | 12 Aug 2026 | |
| 30 Jul 2026 | 10-Q | 30 Jun 2026 | |
| 30 Jul 2026 | 8-K | 28 Jul 2026 | |
| 18 Jun 2026 | 8-K | 18 Jun 2026 | |
| 16 Jun 2026 | 8-K | 15 Jun 2026 | |
| 9 Jun 2026 | 8-K | 8 Jun 2026 | |
| 5 Jun 2026 | 8-K | 2 Jun 2026 | |
| 7 May 2026 | 10-Q | 31 Mar 2026 | |
| 7 May 2026 | 8-K | 7 May 2026 | |
| 28 Apr 2026 | 8-K | 28 Apr 2026 | |
| 20 Apr 2026 | ARS | 31 Jan 2026 | |
| 20 Apr 2026 | DEFA14A | – | |
| 20 Apr 2026 | DEF 14A | 2 Jun 2026 | |
| 25 Mar 2026 | 8-K | 24 Mar 2026 | |
| 19 Feb 2026 | 10-K | 31 Dec 2025 | |
| 19 Feb 2026 | 8-K | 19 Feb 2026 | |
| 12 Feb 2026 | 8-K | 12 Feb 2026 | |
| 12 Jan 2026 | 8-K | 12 Jan 2026 | |
| 29 Dec 2025 | 8-K | 29 Dec 2025 | |
| 4 Nov 2025 | 10-Q | 30 Sep 2025 | |
| 4 Nov 2025 | 8-K | 4 Nov 2025 | |
| 24 Sep 2025 | UPLOAD | – | |
| 18 Sep 2025 | CORRESP | – | |
| 21 Aug 2025 | UPLOAD | – | |
| 19 Aug 2025 | 8-K | 19 Aug 2025 | |
| 7 Aug 2025 | 10-Q | 30 Jun 2025 | |
| 7 Aug 2025 | 8-K | 5 Aug 2025 | |
| 7 Aug 2025 | 8-K | 7 Aug 2025 | |
| 28 Jul 2025 | 8-K | 28 Jul 2025 | |
| 17 Jun 2025 | 8-K | 17 Jun 2025 | |
| 6 May 2025 | 10-Q | 31 Mar 2025 | |
| 6 May 2025 | 8-K | 6 May 2025 | |
| 5 May 2025 | 8-K | 5 May 2025 | |
| 30 Apr 2025 | ARS | 31 Dec 2024 | |
| 30 Apr 2025 | DEFA14A | – | |
| 30 Apr 2025 | DEF 14A | 17 Jun 2025 | |
| 28 Mar 2025 | 8-K | 28 Mar 2025 | |
| 27 Feb 2025 | 10-K | 31 Dec 2024 | |
| 27 Feb 2025 | 8-K | 27 Feb 2025 | |
| 13 Jan 2025 | 8-K | 13 Jan 2025 | |
| 3 Jan 2025 | 8-K | 31 Dec 2024 | |
| 2 Dec 2024 | 8-K | 27 Nov 2024 | |
| 27 Nov 2024 | 8-K | 26 Nov 2024 | |
| 7 Nov 2024 | 10-Q | 30 Sep 2024 | |
| 7 Nov 2024 | 8-K | 7 Nov 2024 | |
| 18 Oct 2024 | 8-K | 18 Oct 2024 | |
| 8 Aug 2024 | 10-Q | 30 Jun 2024 | |
| 8 Aug 2024 | 8-K | 8 Aug 2024 |
1–50 of 150
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 14 Oct 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 2,118 | $59.52 | $126.1K | 1,291,976 | 16 Oct 2026 |
| 14 Oct 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 382 | $60.14 | $23.0K | 1,291,594 | 16 Oct 2026 |
| 9 Oct 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 192 | $64.26 | $12.3K | 105,272 | 13 Oct 2026 |
| 7 Oct 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 2,447 | $63.38 | $155.1K | 1,294,147 | 9 Oct 2026 |
| 7 Oct 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 53 | $63.95 | $3.4K | 1,294,094 | 9 Oct 2026 |
| 6 Oct 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 435 | $64.16 | $27.9K | 105,272 | 7 Oct 2026 |
| 5 Oct 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 1,638 | $64.03 | $104.9K | 105,272 | 7 Oct 2026 |
| 30 Sep 2026 | Steele Glenn Jr Md PhdDirector | Sale under a trading plan | 12,000 | $65.16 | $781.9K | 22,500 | 2 Oct 2026 |
| 17 Sep 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 9,624 | $67.83 | $652.8K | 1,296,970 | 18 Sep 2026 |
| 17 Sep 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 376 | $68.45 | $25.7K | 1,296,594 | 18 Sep 2026 |
| 16 Sep 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 2,994 | $66.58 | $199.3K | 1,313,600 | 18 Sep 2026 |
| 16 Sep 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 7,006 | $67.35 | $471.9K | 1,306,594 | 18 Sep 2026 |
| 10 Sep 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 10,000 | $67.34 | $673.4K | 1,316,594 | 11 Sep 2026 |
| 9 Sep 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 9,428 | $67.79 | $639.1K | 1,327,166 | 11 Sep 2026 |
| 9 Sep 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 572 | $68.67 | $39.3K | 1,326,594 | 11 Sep 2026 |
| 27 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 11,890 | $71.55 | $850.7K | 1,337,204 | 28 Aug 2026 |
| 27 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 610 | $72.22 | $44.1K | 1,336,594 | 28 Aug 2026 |
| 26 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 6,874 | $72.74 | $500.0K | 1,354,720 | 28 Aug 2026 |
| 26 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 5,626 | $73.18 | $411.7K | 1,349,094 | 28 Aug 2026 |
| 20 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 9,419 | $70.78 | $666.7K | 1,364,675 | 21 Aug 2026 |
| 20 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 2,390 | $71.88 | $171.8K | 1,362,285 | 21 Aug 2026 |
| 20 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 691 | $72.92 | $50.4K | 1,361,594 | 21 Aug 2026 |
| 19 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 5,335 | $72.86 | $388.7K | 1,381,259 | 21 Aug 2026 |
| 19 Aug 2026 | Schmertzler MichaelDirector | Sale under a trading plan | 7,165 | $73.67 | $527.8K | 1,374,094 | 21 Aug 2026 |
| 17 Aug 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 1,844 | $72.39 | $133.5K | 106,241 | 19 Aug 2026 |
| 17 Aug 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 969 | $72.90 | $70.6K | 105,272 | 19 Aug 2026 |
| 4 Aug 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER | Sale under a trading plan | 10,292 | $68.57 | $705.7K | 383,868 | 6 Aug 2026 |
| 14 Jul 2026 | Gravier PierreCHIEF FINANCIAL OFFICER | Sale under a trading plan | 3,494 | $80.35 | $280.7K | 83,986 | 16 Jul 2026 |
| 9 Jul 2026 | Smith Mary L.Director | Sale under a trading plan | 10,000 | $90.00 | $900.0K | 21,813 | 13 Jul 2026 |
| 9 Jul 2026 | Smith Mary L.Director | Sale under a trading plan | 5,834 | $90.00 | $525.1K | 21,813 | 13 Jul 2026 |
| 9 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 2,464 | $90.25 | $222.4K | 60,299 | 13 Jul 2026 |
| 7 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 3,956 | $87.17 | $344.8K | 80,956 | 8 Jul 2026 |
| 7 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 11,369 | $89.03 | $1.0M | 69,587 | 8 Jul 2026 |
| 7 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 9,288 | $89.44 | $830.7K | 60,299 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 313 | $83.10 | $26.0K | 107,225 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 833 | $84.41 | $70.3K | 106,392 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 519 | $85.84 | $44.6K | 105,873 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 601 | $86.38 | $51.9K | 105,272 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 387 | $83.10 | $32.2K | 107,698 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 1,036 | $84.41 | $87.4K | 106,662 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 645 | $85.84 | $55.4K | 106,017 | 8 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sale under a trading plan | 745 | $86.38 | $64.4K | 105,272 | 8 Jul 2026 |
| 6 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 426 | $85.28 | $36.3K | 60,684 | 8 Jul 2026 |
| 6 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 385 | $86.34 | $33.2K | 60,299 | 8 Jul 2026 |
| 6 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 8,786 | $85.35 | $749.9K | 70,389 | 8 Jul 2026 |
| 6 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 10,090 | $86.32 | $871.0K | 60,299 | 8 Jul 2026 |
| 6 Jul 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 2,474 | $87.03 | $215.3K | 60,299 | 8 Jul 2026 |
| 26 Jun 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 412 | $85.23 | $35.1K | 60,137 | 30 Jun 2026 |
| 26 Jun 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 7,718 | $85.26 | $658.0K | 60,137 | 30 Jun 2026 |
| 25 Jun 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sale under a trading plan | 582 | $85.24 | $49.6K | 60,556 | 26 Jun 2026 |
1–50 of 150
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 9 Oct 2026 | Boulding Mark ElliottOfficer | 192 | $12.3K | 9 Oct 2026 |
| 7 Oct 2026 | Section Six Partners, L.P.Affiliate of Director | 10,000 | $643.5K | 7 Oct 2026 |
| 6 Oct 2026 | Boulding Mark ElliottOfficer | 435 | $27.9K | 6 Oct 2026 |
| 5 Oct 2026 | Boulding Mark ElliottOfficer | 1,638 | $104.9K | 5 Oct 2026 |
| 30 Sep 2026 | STEELE GLENN JR MD PHDDirector | 12,000 | $781.9K | 30 Sep 2026 |
| 9 Sep 2026 | Section Six Partners, L.P.Affiliate of Director | 40,000 | $2.7M | 9 Sep 2026 |
| 19 Aug 2026 | Michael SchmertzlerDirector | 50,000 | $3.6M | 19 Aug 2026 |
| 17 Aug 2026 | Boulding Mark ElliottOfficer | 2,813 | $201.7K | 17 Aug 2026 |
| 4 Aug 2026 | Klein Matthew B.Officer, Director | 10,292 | $705.8K | 4 Aug 2026 |
| 14 Jul 2026 | Gravier PierreOfficer | 3,494 | $280.7K | 14 Jul 2026 |
| 9 Jul 2026 | Almstead Neil GregoryOfficer | 2,464 | $222.4K | 9 Jul 2026 |
| 9 Jul 2026 | Smith Mary L.Director | 15,834 | $1.4M | 9 Jul 2026 |
| 7 Jul 2026 | Almstead Neil GregoryOfficer | 24,613 | $2.2M | 7 Jul 2026 |
| 6 Jul 2026 | Boulding Mark ElliottOfficer | 5,079 | $427.3K | 6 Jul 2026 |
| 6 Jul 2026 | Almstead Neil GregoryOfficer | 22,161 | $1.9M | 6 Jul 2026 |
| 26 Jun 2026 | Almstead Neil GregoryOfficer | 8,130 | $693.1K | 26 Jun 2026 |
| 25 Jun 2026 | Almstead Neil GregoryOfficer | 20,960 | $1.8M | 25 Jun 2026 |
| 24 Jun 2026 | Almstead Neil GregoryOfficer | 5,323 | $452.6K | 24 Jun 2026 |
| 22 Jun 2026 | Almstead Neil GregoryOfficer | 23,749 | $1.9M | 22 Jun 2026 |
| 17 Jun 2026 | Boulding Mark ElliottOfficer | 10,522 | $827.6K | 17 Jun 2026 |
| 17 Jun 2026 | Utter Christine MarieOfficer | 19,686 | $1.5M | 17 Jun 2026 |
| 10 Jun 2026 | Pauwels EricOfficer | 21,277 | $1.6M | 10 Jun 2026 |
| 15 May 2026 | Boulding Mark ElliottOfficer | 2,812 | $203.7K | 15 May 2026 |
| 14 May 2026 | Klein Matthew B.Officer, Director | 2,572 | $186.4K | 14 May 2026 |
| 14 May 2026 | Klein Matthew B.Officer, Director | 10,000 | $730.8K | 14 May 2026 |
| 8 May 2026 | Boulding Mark ElliottOfficer | 3,540 | $279.6K | 8 May 2026 |
| 21 Apr 2026 | Klein Matthew B.Officer, Director | 2,850 | $202.2K | 21 Apr 2026 |
| 6 Apr 2026 | Boulding Mark ElliottOfficer | 2,265 | $157.3K | 6 Apr 2026 |
| 2 Apr 2026 | Golden Lee ScottOfficer | 829 | $56.4K | 2 Apr 2026 |
| 1 Apr 2026 | Almstead Neil GregoryOfficer | 52,003 | $3.6M | 1 Apr 2026 |
| 12 Mar 2026 | Klein Matthew B.Officer, Director | 2,662 | $170.6K | 12 Mar 2026 |
| 10 Mar 2026 | Okey StephanieDirector | 15,167 | $1.1M | 10 Mar 2026 |
| 5 Mar 2026 | Almstead Zheng YangMember of immediate family of any of the foregoing | 3,989 | $252.8K | 5 Mar 2026 |
| 5 Mar 2026 | Okey StephanieDirector | 6,333 | $401.4K | 5 Mar 2026 |
| 5 Mar 2026 | Golden Lee ScottOfficer | 10,000 | $633.8K | 5 Mar 2026 |
| 19 Feb 2026 | Boulding Mark ElliottOfficer | 3,019 | $207.0K | 19 Feb 2026 |
| 18 Feb 2026 | Almstead Zheng YangMember of immediate family of any of the foregoing | 65 | $4.5K | 18 Feb 2026 |
| 18 Feb 2026 | Golden Lee ScottOfficer | 2,484 | $172.3K | 18 Feb 2026 |
| 18 Feb 2026 | Utter Christine MarieOfficer | 2,494 | $173.0K | 18 Feb 2026 |
| 18 Feb 2026 | Gravier PierreOfficer | 2,992 | $207.5K | 18 Feb 2026 |
| 18 Feb 2026 | Pauwels EricOfficer | 3,019 | $209.4K | 18 Feb 2026 |
| 18 Feb 2026 | Almstead Neil GregoryOfficer | 3,056 | $212.0K | 18 Feb 2026 |
| 18 Feb 2026 | Boulding Mark ElliottOfficer | 3,081 | $213.7K | 18 Feb 2026 |
| 18 Feb 2026 | Klein Matthew B.Officer, Director | 7,371 | $511.2K | 18 Feb 2026 |
| 17 Feb 2026 | Boulding Mark ElliottOfficer | 2,813 | $194.5K | 17 Feb 2026 |
| 9 Jan 2026 | Boulding Mark ElliottOfficer | 2,314 | $180.3K | 9 Jan 2026 |
| 9 Jan 2026 | Pauwels EricOfficer | 2,746 | $213.9K | 9 Jan 2026 |
| 8 Jan 2026 | Almstead Zheng YangMember of immediate family of any of the foregoing | 59 | $4.5K | 8 Jan 2026 |
| 8 Jan 2026 | Golden Lee ScottOfficer | 866 | $66.2K | 8 Jan 2026 |
| 8 Jan 2026 | Almstead Neil GregoryOfficer | 881 | $67.4K | 8 Jan 2026 |
1–50 of 80
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 15 May 2026 | JANUS HENDERSON GROUP PLC | 13G amended | 8.7% | 7.2M |
| 15 May 2026 | The Toronto-Dominion Bank | 13G amended | 3.7% | 3.0M |
| 30 Apr 2026 | Vanguard Capital Management | 13G | 5.17% | 4.3M |
| 29 Apr 2026 | Vanguard Portfolio Management | 13G | 5.88% | 4.9M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | JANUS HENDERSON GROUP PLC | 13G | 6% | 4.9M |
| 13 Feb 2026 | The Toronto-Dominion Bank | 13G | 5.2% | 4.1M |
| 10 Feb 2026 | Wellington Management Group LLP | 13G amended | 4.82% | 3.9M |
| 9 Feb 2026 | STATE STREET CORPORATION | 13G | 5.2% | 4.2M |
| 4 Dec 2025 | BlackRock, Inc. | 13G amended | 14.8% | 11.9M |
| 14 Nov 2025 | Armistice Capital, LLC | 13G amended | 4.08% | 3.3M |
| 30 Oct 2025 | The Vanguard Group | 13G amended | 10.43% | 8.3M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
No House trades in this company.
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
Shares short, each settlement
| 30 Sep 2026 | 9.2M | -5.86% | 6.14 |
| 15 Sep 2026 | 9.7M | -0.91% | 11.03 |
| 31 Aug 2026 | 9.8M | -3.84% | 12.13 |
| 14 Aug 2026 | 10.2M | -3.27% | 10.82 |
| 31 Jul 2026 | 10.6M | +7.45% | 7.52 |
| 15 Jul 2026 | 9.8M | -43.21% | 4.75 |
| 30 Jun 2026 | 17.3M | +46.94% | 5.36 |
| 15 Jun 2026 | 11.8M | +10.4% | 7.82 |
| 29 May 2026 | 10.7M | +4.23% | 11.08 |
| 15 May 2026 | 10.2M | +4.97% | 5.99 |
1–10 of 211
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
426
quarter to 30 Jun 2026
Added or new
207
since 31 Mar 2026
Trimmed
112
in the quarter
Largest holder
BlackRock, Inc.
$1.1B
The 60 largest of 426 funds, by value
| BlackRock, Inc. | $1.1B | 14.0M | +1.0M | Added | 0.02% | Filing ↗ |
| RTW Investments, LP | $631.9M | 7.7M | 0 | Held | 5.39% | Filing ↗ |
| Jupiter Topco LLC | $590.2M | 7.2M | – | first | 0.24% | Filing ↗ |
| Vanguard Portfolio Management LLC | $402.0M | 4.9M | +123.5K | Added | 0.02% | Filing ↗ |
| State Street Corp. | $375.1M | 4.6M | +252.4K | Added | 0.01% | Filing ↗ |
| Wellington Management Group LLP | $336.7M | 4.1M | +185.7K | Added | 0.06% | Filing ↗ |
| Vanguard Capital Management LLC | $305.0M | 3.7M | +62.9K | Added | 0.01% | Filing ↗ |
| Geode Capital Management, LLC | $180.1M | 2.2M | -2.6K | Trimmed | 0.01% | Filing ↗ |
| Toronto Dominion Bank | $176.7M | 2.2M | -860.1K | Trimmed | 0.30% | Filing ↗ |
| Westfield Capital Management Co. LP | $159.6M | 2.0M | +2.0M | New | 0.52% | Filing ↗ |
| Hood River Capital Management LLC | $141.8M | 1.7M | +74.1K | Added | 1.03% | Filing ↗ |
| William Blair Investment Management, LLC | $140.5M | 1.7M | +1.7M | New | 0.42% | Filing ↗ |
| D. E. Shaw & Co., Inc. | $126.3M | 1.5M | -91.5K | Trimmed | 0.08% | Filing ↗ |
| Tang Capital Management LLC | $122.4M | 1.5M | 0 | Held | 5.59% | Filing ↗ |
| Bank of America Corp. | $118.5M | 1.5M | -434.6K | Trimmed | 0.01% | Filing ↗ |
| Driehaus Capital Management LLC | $117.5M | 1.4M | +424.3K | Added | 0.68% | Filing ↗ |
| FMR LLC | $114.1M | 1.4M | -130.1K | Trimmed | 0.01% | Filing ↗ |
| Jefferies Financial Group Inc. | $110.7M | 1.4M | +2.6K | Added | 1.04% | Filing ↗ |
| Fuller & Thaler Asset Management, Inc. | $94.4M | 1.2M | +1.2M | New | 0.26% | Filing ↗ |
| Pictet Asset Management Holding SA | $93.6M | 1.1M | -35.9K | Trimmed | 0.09% | Filing ↗ |
| Price T Rowe Associates Inc. | $90.9M | 1.1M | +639.4K | Added | 0.01% | Filing ↗ |
| Morgan Stanley | $90.0M | 1.1M | +429.5K | Added | 0.01% | Filing ↗ |
| Armistice Capital, LLC | $87.4M | 1.1M | -1.0M | Trimmed | 2.42% | Filing ↗ |
| Blue Sparrow, LLC | $85.7M | 1.1M | +860.1K | Added | 0.83% | Filing ↗ |
| Franklin Resources Inc. | $83.8M | 1.0M | -94.1K | Trimmed | 0.02% | Filing ↗ |
| Invesco Ltd. | $76.8M | 941.6K | +76.1K | Added | 0.01% | Filing ↗ |
| Palo Alto Investors LP | $75.0M | 918.8K | -2.8K | Trimmed | 10.36% | Filing ↗ |
| Northern Trust Corp. | $71.8M | 880.0K | +73.8K | Added | 0.01% | Filing ↗ |
| Charles Schwab Investment Management Inc. | $64.4M | 790.1K | +58.5K | Added | 0.01% | Filing ↗ |
| Citadel Advisors LLC | $61.0M | 747.8K | +362.6K | Added | 0.04% | Filing ↗ |
| Renaissance Technologies LLC | $59.0M | 723.5K | +190.2K | Added | 0.08% | Filing ↗ |
| Boston Partners | $58.6M | 718.6K | +71.1K | Added | 0.05% | Filing ↗ |
| Jupiter Asset Management Ltd | $57.7M | 707.5K | -4.0K | Trimmed | 0.29% | Filing ↗ |
| Marshall Wace, LLP | $57.5M | 704.8K | +244.1K | Added | 0.05% | Filing ↗ |
| JPMorgan Chase & Co. | $56.1M | 684.0K | +338.0K | Added | 0.00% | Filing ↗ |
| Arrowstreet Capital, Limited Partnership | $53.4M | 654.4K | +542.8K | Added | 0.02% | Filing ↗ |
| Dimensional Fund Advisors LP | $52.0M | 637.7K | -253.0K | Trimmed | 0.01% | Filing ↗ |
| Goldman Sachs Group Inc. | $50.4M | 618.2K | -209.4K | Trimmed | 0.01% | Filing ↗ |
| SG Americas Securities, LLC | $49.4M | 605.6K | -274.1K | Trimmed | 0.03% | Filing ↗ |
| Loomis Sayles & Co. L P | $48.2M | 590.4K | +96.8K | Added | 0.06% | Filing ↗ |
| Lord, Abbett & Co. LLC | $48.1M | 590.1K | -27.0K | Trimmed | 0.14% | Filing ↗ |
| Vanguard Fiduciary Trust Co. | $48.0M | 587.9K | +34.2K | Added | 0.01% | Filing ↗ |
| Nuveen, LLC | $47.6M | 583.8K | -83.2K | Trimmed | 0.01% | Filing ↗ |
| Bank of New York Mellon Corp | $45.1M | 553.5K | +30.7K | Added | 0.01% | Filing ↗ |
| Principal Financial Group Inc. | $44.2M | 541.6K | +26.6K | Added | 0.02% | Filing ↗ |
| Voya Investment Management LLC | $44.0M | 539.3K | +196.7K | Added | 0.04% | Filing ↗ |
| Ensign Peak Advisors, Inc | $41.4M | 508.1K | -74.3K | Trimmed | 0.07% | Filing ↗ |
| American Century Companies Inc. | $40.9M | 501.0K | +496.0K | Added | 0.02% | Filing ↗ |
| Federated Hermes, Inc. | $39.4M | 483.4K | +257.5K | Added | 0.06% | Filing ↗ |
| Manufacturers Life Insurance Company, the | $36.1M | 442.0K | +16.7K | Added | 0.03% | Filing ↗ |
1–50 of 60
Executive pay and performance
What the chief executive and the other named officers were paid, as reported and as actually paid, next to the shareholder return and net income, from each proxy's pay-versus-performance table.
Pay versus performance
6 fiscal years · from each proxy (DEF 14A)| Fiscal year | CEO pay, as reported | CEO pay, actually paid | Other officers, as reported (average) | Other officers, actually paid (average) | Shareholder return, $100 | Peer return, $100 | Net income | Revenue | Proxy |
|---|---|---|---|---|---|---|---|---|---|
| FY ending 31 Dec 2025 | $23.3M | $41.2M | $3.4M | $7.1M | $125 | $120 | $683.0M | $1.73B | DEF 14A 20 Apr 2026 |
| FY ending 31 Dec 2024 | $7.4M | $14.7M | $2.3M | $4.5M | $74 | $91 | $-363.3M | $806.8M | DEF 14A 20 Apr 2026 |
| FY ending 31 Dec 2023 | $8.9MMatthew Klein$5.7MStuart Peltz | $4.8M$-3.5M | $2.4M | $0.8M | $45 | $92 | $-626.6M | $937.8M | DEF 14A 20 Apr 2026 |
| FY ending 31 Dec 2022 | $7.2M | $5.4M | $3.4M | $2.7M | $63 | $89 | $-559.0M | $698.8M | DEF 14A 20 Apr 2026 |
| FY ending 31 Dec 2021 | $11.0M | $-4.9M | $4.3M | $-1.0M | $65 | $99 | $-523.9M | $538.6M | DEF 14A 20 Apr 2026 |
| FY ending 31 Dec 2020 | $10.6M | $12.6M | $4.0M | $2.6M | $127 | $126 | $-438.2M | $380.8M | DEF 14A 30 Apr 2025 |
Each year from the newest proxy that reports it. Pay actually paid follows the SEC's definition and can be below zero when share awards fall in value. n the proxy's net income differs from the 10-K or was tagged without its scale: hover for which.
Shareholder votes
The vote count on every proposal at each meeting, from the company's 8-K.
| Proposal | For | Against or withheld | Abstain | Broker non-votes | For, % of for and against | Result |
|---|---|---|---|---|---|---|
| Proposal 1 (the filing doesn't name it) | ||||||
| Jessica Chutter | 71,945,515 | 737,780 | – | 3,858,311 | 99.0% | – |
| Matthew B. Klein, M.D., M.S., F.A.C.S. | 71,550,878 | 1,132,417 | – | 3,858,311 | 98.4% | – |
| Stephanie S. Okey, M.S. | 68,902,707 | 3,780,588 | – | 3,858,311 | 94.8% | – |
| Jerome B. Zeldis, M.D., Ph.D. | 69,821,943 | 2,861,352 | – | 3,858,311 | 96.1% | – |
Counts as the company reports them in its 8-K. A result shows when the filing states one. Meetings since 2023.
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics, Inc.this company | $5.0B | $1.0B | -42.8% | 12.5% | -3.8% | – | – | 25.4× |
| Eli Lilly & Co. | $1.20T | $79.7B | 49.6% | – | 33.5% | 78.8% | 42.7× | – |
| Johnson & Johnson | $635.2B | $99.3B | 7.8% | – | 16.2% | 19.7% | 40.0× | – |
| AbbVie Inc. | $504.8B | $64.4B | 10.4% | 26.2% | 9.8% | – | 80.7× | 23.0× |
| Merck & Co., Inc. | $358.4B | $66.6B | 4.6% | – | 4.8% | 7.6% | 116.2× | – |
| Novartis AG | $288.3B | $54.5B | 8.4% | – | – | 30.3% | 21.1× | – |
| AstraZeneca PLC | $266.0B | $58.7B | 8.6% | 23.4% | 17.4% | 21.0% | 26.2× | – |
| Abbott Laboratories | $179.4B | $46.6B | 8.1% | 15.8% | 11.6% | 10.6% | 33.6× | 19.2× |
| Novo Nordisk A/S | $174.3B | $46.8B | 6.4% | 41.3% | 33.1% | 52.8% | 11.3× | – |
| Pfizer Inc. | $171.1B | $63.7B | -0.2% | – | 6.8% | 5.1% | 39.5× | – |
| Vertex Pharmaceuticals Inc. | $132.7B | $12.6B | 10.2% | 38.0% | 35.0% | 21.8% | 30.5× | 25.3× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence